Les Laboratoires Servier SAS of France has extended its reach into the rare disease space with the acquisition of the muscular dystrophy business of Edgewise Therapeutics Inc of Boulder Colorado, US. The lead asset is sevasemten, a small molecule drug that is being developed for both Becker muscular dystrophy and Duchene muscular dystrophy. The two disorders are caused by mutations in the DMD gene which encodes for the dystrophin protein.
